Outcome for Pediatric Recipients of Macrosteatotic Liver Grafts From Living Donors

Rie Irie, Atsuko Nakazawa, Seisuke Sakamoto, Masahiro Takeda, Yusuke Yanagi, Seiichi Shimizu, Hajime Uchida, Akinari Fukuda, Mureo Kasahara – 20 April 2020 – In deceased donor liver transplantation, a donor liver with moderate (>30%) macrosteatosis used to be considered inappropriate for grafting. We examined the outcomes of children who underwent living donor liver transplantation (LDLT) at the National Center for Child Health and Development whose donor livers had moderate‐to‐severe macrosteatosis.

Molecular Targets in Cholangiocarcinoma

Colm J. O’Rourke, Patricia Munoz‐Garrido, Jesper B. Andersen – 18 April 2020 – Cholangiocarcinoma (CCA) encompasses a heterogeneous collection of malignancies for which diagnostic biomarkers are lacking and population screening is infeasible because of its status as a rare disease. Coupled with high postsurgical recurrence rates among the minority of patients diagnosed at resectable stages, systemic clinical management will inevitably be required for the majority of patients with CCA with recurrent and advanced disease.

Loss of c‐Jun N‐terminal Kinase 1 and 2 Function in Liver Epithelial Cells Triggers Biliary Hyperproliferation Resembling Cholangiocarcinoma

Francisco Javier Cubero, Mohamed Ramadan Mohamed, Marius M. Woitok, Gang Zhao, Maximilian Hatting, Yulia A. Nevzorova, Chaobo Chen, Johannes Haybaeck, Alain Bruin, Matias A. Avila, Mark V. Boekschoten, Roger J. Davis, Christian Trautwein – 16 April 2020 – Targeted inhibition of the c‐Jun N‐terminal kinases (JNKs) has shown therapeutic potential in intrahepatic cholangiocarcinoma (CCA)‐related tumorigenesis. However, the cell‐type‐specific role and mechanisms triggered by JNK in liver parenchymal cells during CCA remain largely unknown.

Subscribe to